Trial · NCT02075463
Outcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Demonstrating an Increase in Hgb of >=1 g/dL (if Baseline Hgb is <9.5 g/dL), or >=0.5 g/dL (if Baseline Hgb is 9.5-<10 g/dL), or Stay Within Target Range and do Not Drop by >0.5 g/dL (if Baseline Hgb is >= 10 g/dL) at Week 16 | Week 16 | ITT population: participants who received at least one dose of drug, have a baseline Hgb and at least one corresponding on treatment Hgb assessment. | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Hgb Levels at Week 16 | Week 16 | ITT population. | g/dL | MEAN |
| SECONDARY | Percentage of Time (Days) Hgb Levels Within, Below and Above Target Range at the Indicated Time Point | Week 12 to Week 16 | ITT population. | Percentage of days | MEAN |
| SECONDARY | Number of Participants Achieving at Least 1 g/dL Increase in Hgb From Baseline at Week 16 | Baseline and Week 16 | ITT population. | Participants | NUMBER |
| SECONDARY | Number of Participants With Hgb in the Target Range at Week 16 | Week 16 | ITT population | Participants | NUMBER |
| SECONDARY | Number of Participants Reaching Pre-defined Hgb Stopping Criteria | Up to Week 16 | ITT population | Participants | NUMBER |
| SECONDARY | Percent Change From Baseline in Hepcidin at Week 16 | Baseline (Day 1) and Week 16 | ITT population | Percent change in hepcidin | GEOMETRIC_MEAN |
| SECONDARY | Change From Baseline in Ferritin at Week 16 | Baseline (Day 1) and Week 16 | ITT population | Micrograms/Liter | MEAN |
| SECONDARY | Change From Baseline in Transferrin at Week 16 | Baseline (Day 1) and Week 16 | ITT population | Percent change | MEAN |
| SECONDARY | Percent Change From Baseline in Transferrin Saturation at Week 16 | Baseline (Day 1) and Week 16 | ITT population | Percent change in transferrin | GEOMETRIC_MEAN |
| SECONDARY | Change From Baseline in Total Iron at Week 16 | Baseline (Day 1) and Week 16 | ITT population | Micromoles (µmol)/L | NUMBER |
| SECONDARY | Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 16 | Baseline (Day 1) and Week 16 | ITT population | µmol/ L | NUMBER |
| SECONDARY | Reticulocyte Hgb Content (CHr) at Week 16 | Week 16 | Safety population consisted of all participants who received at least one dose of study drug | Picogram (pg) | NUMBER |
| SECONDARY | Mean Corpuscular Volume (MCV) at Week 16 | Week 16 | Safety population | Femtoliter (fL) | NUMBER |
| SECONDARY | Mean Corpuscular Hemoglobin (MCH) at Week 16 | Week 16 | Safety population | pg | NUMBER |
| SECONDARY | Change From Baseline in Hematocrit at Week 16 | Baseline (Day 1) and Week 16 | ITT population | Fraction of 1 | NUMBER |
| SECONDARY | Change From Baseline in Red Blood Cell (RBC) at Week 16 | Baseline (Day 1) and Week 16 | ITT population | 10^12/L | NUMBER |
| SECONDARY | Change From Baseline in Reticulocyte Number at Week 16 | Baseline (Day 1) and Week 16 | ITT population | 10^12/L | NUMBER |
| SECONDARY | Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF) | Baseline (Day 1) to Week 16 | ITT population | Percent change | GEOMETRIC_MEAN |
| SECONDARY | Maximum Observed Change From Baseline in Erythropoietin (EPO) | Baseline (Day 1) to Week 16 | ITT population | international units(IU)/Liter (L) | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02075463/outcomes